Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction

Nature Communications

Volumn 7, Issue , 2016, Pages

  Zhao, Shuting ^a,b   Xu, Zhaobin ^b,c   Wang, Hai ^a,b   Reese, Benjamin E ^a,b   Gushchina, Liubov V ^b,c   Jiang, Meng ^b,c   Agarwal, Pranay ^a,b   Xu, Jiangsheng ^a,b   Zhang, Mingjun ^a,b   Shen, Rulong ^c   Liu, Zhenguo ^b,c   Weisleder, Noah ^b,c   He, Xiaoming ^a,b,d  

^a The Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; TRANSCRIPTION FACTOR NKX2.5;

ANIMAL; BIOENGINEERING; CELLS AND CELL COMPONENTS; IMMUNE RESPONSE; REGROWTH; SURVIVAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENGINEERING; CARDIAC MUSCLE CELL; CELL AGGREGATION; CELL ENCAPSULATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CONTROLLED STUDY; DEGRADATION; GRANULOMA; HEART FUNCTION; HEART INFARCTION; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION PROFILING; GENETICS; INJECTION; KNOCKOUT MOUSE; METABOLISM; MICROCAPSULE; MOUSE EMBRYONIC STEM CELL; PROCEDURES;

ANIMALIA;

ANIMALS; BIOENGINEERING; CAPSULES; CELL AGGREGATION; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION PROFILING; INJECTIONS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOUSE EMBRYONIC STEM CELLS; MYOCARDIAL INFARCTION; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84993978152     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13306     Document Type: Article

References (60)

1. Mozaffarian, D. et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133, e38-e360 (2016).
2. Laslett, L. J. et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J. Am. Coll. Cardiol. 60, S1-49 (2012).
3. Segers, V. F. & Lee, R. T. Stem-cell therapy for cardiac disease. Nature 451, 937-942 (2008).
4. Laflamme, M. A. & Murry, C. E. Heart regeneration. Nature 473, 326-335 (2011).
5. Sanganalmath, S. K. & Bolli, R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 113, 810-834 (2013).
6. Steinhauser, M. L. & Lee, R. T. Regeneration of the heart. EMBO Mol. Med. 3, 701-712 (2011).
7. Hattori, F. et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat. Methods 7, 61-66 (2010).
8. Christoforou, N. et al. Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. PLOS ONE 5, e11536 (2010).
9. Vunjak-Novakovic, G. et al. Challenges in cardiac tissue engineering. Tissue Eng. Part B Rev. 16, 169-187 (2010).
10. Hirt, M. N., Hansen, A. & Eschenhagen, T. Cardiac tissue engineering: state of the art. Circ. Res. 114, 354-367 (2014).
11. de Almeida, P. E., Ransohoff, J. D., Nahid, A. & Wu, J. C. Immunogenicity of pluripotent stem cells and their derivatives. Circ. Res. 112, 549-561 (2013).
12. Pearl, J. I. et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8, 309-317 (2011).
13. Zhao, T., Zhang, Z. N., Rong, Z. & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212-215 (2011).
14. Ankrum, J. A., Ong, J. F. & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32, 252-260 (2014).
15. Nian, M., Lee, P., Khaper, N. & Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94, 1543-1553 (2004).
16. van den Akker, F., Deddens, J. C., Doevendans, P. A. & Sluijter, J. P. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim. Biophys. Acta 1830, 2449-2458 (2013).
17. Suzuki, K. et al. Role of interleukin-1beta in acute inflammation and graft death after cell transplantation to the heart. Circulation 110, II219-II224 (2004).
18. Qian, L., Wu, Z. & Shen, J. Advances in the treatment of acute graft-versus-host disease. J. Cell Mol. Med. 17, 966-975 (2013).
19. Ram, R., Yeshurun, M., Vidal, L., Shpilberg, O. & Gafter-Gvili, A. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versushost- disease-systematic review and meta-analysis. Leuk. Res. 38, 352-360 (2014).
20. Nussbaum, J. et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. Faseb. J. 21, 1345-1357 (2007).
21. Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L. & Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998-1004 (2013).
22. Blum, B., Bar-Nur, O., Golan-Lev, T. & Benvenisty, N. The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat. Biotechnol. 27, 281-287 (2009).
23. Liu, Y. et al. Transplantation of parthenogenetic embryonic stem cells ameliorates cardiac dysfunction and remodelling after myocardial infarction. Cardiovasc. Res. 97, 208-218 (2013).
24. Shiba, Y. et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322-325 (2012).
25. Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015-1024 (2007).
26. Chen, H. S., Kim, C. & Mercola, M. Electrophysiological challenges of cellbased myocardial repair. Circulation 120, 2496-2508 (2009).
27. Lewis, R., Gaffin, D., Hoefnagels, M. & Parker, B. Life 5th Ed. (McGraw-Hill Higher Education, 2004).
28. Scadden, D. T. The stem-cell niche as an entity of action. Nature 441, 1075-1079 (2006).
29. Zhao, S. et al. Coaxial electrospray of liquid core-hydrogel shell microcapsules for encapsulation and miniaturized 3D culture of pluripotent stem cells. Integr. Biol. 6, 874-884 (2014).
30. Burridge, P. W. et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLOS ONE 6, e18293 (2011).
31. Mummery, C. L. et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ. Res. 111, 344-358 (2012).
32. Hiroi, Y. et al. Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat. Genet. 28, 276-280 (2001).
33. Peterkin, T. & Gibson, A. Patient R. GATA-6 maintains BMP-4 and Nkx2 expression during cardiomyocyte precursor maturation. Embo J. 22, 4260-4273 (2003).
34. Zhang, W. et al. A novel core-shell microcapsule for encapsulation and 3D culture of embryonic stem cells. J. Mater. Chem. B 1, 1002-1009 (2013).
35. Agarwal, P. et al. One-step microfluidic generation of pre-hatching embryo-like core-shell microcapsules for miniaturized 3D culture of pluripotent stem cells. Lab Chip 13, 4525-4533 (2013).
36. Choi, J., Agarwal, P., Huang, H., Zhao, S. & He, X. The crucial role of mechanical heterogeneity in regulating follicle development and ovulation with engineered ovarian microtissue. Biomaterials 35, 5122-5128 (2014).
37. Hsu, Y. M. et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat. Immunol. 8, 198-205 (2007).
38. Rao, W. et al. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials 35, 7762-7773 (2014).
39. Agarwal, P. et al. A biomimetic core-shell platform for miniaturized 3D cell and tissue engineering. Part. Part. Syst. Charact. 32, 809-816 (2015).
40. Mayfield, A. E. et al. The effect of encapsulation of cardiac stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function. Biomaterials 35, 133-142 (2014).
41. Ruland, J. CARD9 signaling in the innate immune response. Ann. N. Y. Acad. Sci. 1143, 35-44 (2008).
42. Ren, J. et al. Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. Am. J. Hypertens 24, 701-707 (2011).
43. Drummond, R. A. et al. CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. PLoS Pathog. 11, e1005293 (2015).
44. Weirather, J. et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ. Res. 115, 55-67 (2014).
45. Montecucco, F. et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur. Heart J. 33, 1964-1974 (2012).
46. Zhao, S. et al. Conformal nanoencapsulation of allogeneic T cells mitigates graft-versus-host disease and retains graft-versus-leukemia activity. ACS Nano 10, 6189-6200 (2016).
47. Barron, M., Gao, M. & Lough, J. Requirement for BMP and FGF signaling during cardiogenic induction in non-precardiac mesoderm is specific, transient, and cooperative. Dev. Dyn. 218, 383-393 (2000).
48. Kawai, T. et al. Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ J. 68, 691-702 (2004).
49. Lough, J. et al. Combined BMP-2 and FGF-4, but neither factor alone, induces cardiogenesis in non-precardiac embryonic mesoderm. Dev. Biol. 178, 198-202 (1996).
50. Alsberg, E., Anderson, K. W., Albeiruti, A., Rowley, J. A. & Mooney, D. J. Engineering growing tissues. Proc. Natl Acad. Sci. USA 99, 12025-12030 (2002).
51. Lee, K. Y. & Mooney, D. J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 37, 106-126 (2012).
52. Rao, W. et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 9, 5725-5740 (2015).
53. Arslan, F. et al. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ. Res. 108, 582-592 (2011).
54. Braunersreuther, V. et al. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb. Haemost. 110, 807-825 (2013).
55. Greer, J. J. et al. Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. 291, H2743-H2751 (2006).
56. Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D.M. & Granger, C. B. in Fundamentals of clinical trials 5th edn. (Springer International Publishing, 2015).
57. Pacher, P., Nagayama, T., Mukhopadhyay, P., Batkai, S. & Kass, D. A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat. Protoc. 3, 1422-1434 (2008).
58. Shettigar, V. et al. Rationally engineered Troponin C modulates in vivo cardiac function and performance in health and disease. Nat. Commun. 7, 10794 (2016).
59. Terrovitis, J. et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J. Am. Coll. Cardiol. 54, 1619-1626 (2009).
60. Wang, H. et al. Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction. J. Cell Mol. Med. 16, 1310-1320 (2012).